Browse the evidence

Disparities in the use of SGLT-2 inhibitors and GLP-1 receptor agonists exist based on race, sex, and socioeconomic status.

Efforts should be made to address these disparities in prescribing practices.

Traditional recommendations for obesity treatment are largely ineffective.

Practitioners should be aware that traditional methods may not yield results.

There has been a revolution in understanding the molecular and neural control of appetite and body weight.

Understanding these mechanisms can inform treatment strategies for obesity.

C-reactive protein levels decreased after one year of GLP1-RA treatment.

Monitoring C-reactive protein levels may help assess the effectiveness of GLP1-RA in IBD.

23% of participants reported any adverse event while using GLP-1RAs, with 7% discontinuing treatment.

While GLP-1RAs are generally well-tolerated, practitioners should monitor for adverse events.

Obesity and its associated conditions significantly impact healthcare systems, life expectancy, and quality of life.

Addressing obesity is crucial for improving healthcare outcomes and quality of life.

Ghrelin is an orexigenic hormone, while GLP-1, GIP, CCK, PYY, and OXM are anorexigenic hormones.

Understanding the roles of these hormones can help in developing targeted interventions for appetite regulation.

Treatment of wild-type mice with linolenic acid reduced food intake and body mass.

Using linolenic acid may help reduce food intake and body mass in certain contexts.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing dementia risk in this population.

Bariatric surgery performed in patients with obesity and end-stage liver disease waiting for liver transplantation is associated with a 5% major post-bariatric surgery complications rate and a 7% 1-year post-liver transplantation mortality.

Bariatric surgery can be considered for patients with obesity awaiting liver transplantation, with a relatively low complication and mortality rate.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Benefits of the intervention were not evident for those entering the trial with a history of cardiovascular disease.

Practitioners should consider individual health histories when recommending lifestyle interventions.

Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.

You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.

Antidiabetic medications can reduce the risk and improve outcomes of cardiovascular diseases.

Consider the cardiovascular benefits when prescribing antidiabetic medications.

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

New approaches in GLP-1RAs development include multi-agonists and combination therapies.

Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.